Search - tctmd.com

Displaying 141 - 160 of 912

Sort: Relevancy | Date

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI

News Daily News

For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI

Michael O'Riordan

February 23, 2023

P2Y12 Monotherapy Better Than Continued DAPT Even After Complex PCI

News Daily News

P2Y12 Monotherapy Better Than Continued DAPT Even After Complex PCI

Yael L. Maxwell

February 06, 2023

Brachytherapy Remains an Option for DES In-Stent Restenosis

News Daily News

Brachytherapy Remains an Option for DES In-Stent Restenosis

Yael L. Maxwell

January 12, 2023

Routine Coronary Tests Prior to Kidney Transplant Questioned

News Daily News

Routine Coronary Tests Prior to Kidney Transplant Questioned

Yael L. Maxwell

January 05, 2023

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

News Daily News

Nuisance Bleeds on DAPT Not Just an Annoyance: TALOS-AMI Analysis

November 30, 2022

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

News Conference News AHA 2022

Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5

Yael L. Maxwell

November 11, 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

News Conference News AHA 2022

RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

November 10, 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

November 06, 2022

New Biomarker-Based Risk Score Performs Well in ACS

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

News Daily News

COVID Drug Paxlovid Interacts With Widely Used CV Meds: Review

October 12, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

TCT 31: Clinical Impact of Genetics on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention Using Drug-Eluting Stent

Presentation TCT 2022

TCT 31: Clinical Impact of Genetics on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention Using Drug-Eluting Stent

Presenter: Seung Hun Lee

September 19, 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presentation TCT 2022

TCT 4: Dual Antiplatelet Therapy for 1 Versus 3 Months in Women and Men at High Bleeding Risk Undergoing Drug-Eluting Stent Implantation

Presenter: Johny Nicolas

September 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.